预约演示

更新于：2025-05-07

GPR88

更新于：2025-05-07

基本信息

别名

G protein coupled receptor 88、G protein-coupled receptor 88、G-protein coupled receptor 88

+ [4]

简介

Orphan G protein-coupled receptor implicated in a large repertoire of behavioral responses that engage motor activities, spatial learning, and emotional processing (By similarity). May play a role in the regulation of cognitive and motor function (By similarity). Couples with the heterotrimeric G protein complex of the G(i) subfamily, consisting of GNAI1, GNB1 and GNG2, thereby acting through a G(i)-mediated pathway (PubMed:35501348). Plays a role in the attenuation of D1 dopamine receptor (D1R)-mediated cAMP response in ciliated cells (PubMed:23936473). In non-ciliated cells, involved in the inhibition of the beta-2 adrenergic receptor (B2AR) response (PubMed:23936473).

关联

项与 GPR88 相关的药物

GPR88 agonists(Acadia Pharmaceuticals)

GPR88激动剂(Acadia Pharmaceuticals)

靶点

GPR88

作用机制

GPR88 激动剂

在研机构

ACADIA Pharmaceuticals, Inc.

原研机构

ACADIA Pharmaceuticals, Inc.

在研适应症

阿尔茨海默症 [+7]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

GPR88 agonist(Bristol-Myers Squibb)

靶点

GPR88

作用机制

GPR88 激动剂

在研机构

Bristol Myers Squibb Co. [+1]

原研机构

Bristol Myers Squibb Co.

在研适应症

神经系统疾病

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

RTI-13951-33

靶点

GPR88

作用机制

GPR88 激动剂

在研机构

Research Triangle Institute

原研机构

Research Triangle Institute

在研适应症

酗酒

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

100 项与 GPR88 相关的临床结果

登录后查看更多信息

100 项与 GPR88 相关的转化医学

登录后查看更多信息

0 项与 GPR88 相关的专利（医药）

登录后查看更多信息

项与 GPR88 相关的文献（医药）

2025-03-01·Neuropharmacology

GPR88 impairs the signaling of kappa opioid receptors in a heterologous system and in primary striatal neurons

Article

作者: Garrigós, Claudia ; Navarro, Gemma ; Lillo, Jaume ; Franco, Rafael ; Rivas-Santisteban, Rafael

The physiological role of GPR88, an orphan G protein-coupled receptor (GPCR) predominantly expressed in the striatum, remains unclear, despite its altered expression in parkinsonian animal models. GPR88 is known to interact with other GPCRs. Specifically, GPR88 expression inhibits signaling mediated by the μ-opioid receptor in cells coexpressing both receptors. The effect of GPR88 on the kappa-opioid receptor (KOR) is less understood. In this study, we examine the interaction between GPR88 and KOR, and the impact of GPR88 expression on KOR-mediated signaling in heterologous cells and primary striatal neurons. Bioluminescence resonance energy transfer and proximity ligation assays revealed an interaction between GPR88 and KOR. Functional assays showed that GPR88 antagonized the effects of U69,593, a selective KOR agonist, on forskolin-stimulated cAMP levels, β-arrestin-2 recruitment, and phosphorylation of extracellular signal-regulated kinases (ERK1/2) in HEK-293T cells coexpressing both receptors. In primary striatal neurons, GPR88 and KOR complexes were observed, with KOR activation effects enhanced when GPR88 expression was suppressed using RNA interference. These results suggest that GPR88 and KOR are coexpressed in striatal neurons, where GPR88 inhibits KOR activation. Notably, the GPR88-KOR heteromer was more prevalent in dopamine D₁-receptor-containing neurons of the direct pathway of the basal ganglia. Given the roles of KORs in dopamine release, motor function regulation, and pain and reward perception, the GPR88-KOR interaction warrants further investigation in the context of neuropathic pain, Parkinson's disease, and neuropsychiatric disorders.

2024-07-11·Journal of Medicinal Chemistry

Discovery of BI-9508, a Brain-Penetrant GPR88-Receptor-Agonist Tool Compound for In Vivo Mouse Studies

Article

作者: Recolet, Mandy ; Schlecker, Annette ; Faye, Vincent ; Eickmeier, Christian ; Young, Kyle ; Steinberg, Edith ; Hoerer, Stefan ; Fer, Mickael ; Frauli, Mélanie ; Klepp, Julian ; Kieffer, Brigitte L. ; Zinser, Alexander ; Lebrun, Louison ; Cui, Yunhai ; Halter, Célia ; Würstle, Klaus ; Breh-Schlanser, Petra ; Schann, Stephan ; Omrani, Azar ; Hoenke, Christoph ; Hucke, Oliver T. ; Heyer, Marjorie ; Amalric, Camille ; Schaeffer, Laurent ; Mayer, Stanislas ; Montel, Florian ; Baron, Luc ; Viloria, Mélanie ; Ben Hamida, Sami ; Franchet, Christel ; Darcq, Emmanuel ; Lotz, Noémie ; Arban, Roberto ; Joseph, Christophe

Decreased activity and expression of the G-protein coupled receptor GPR88 is linked to many behavior-linked neurological disorders. Published preclinical GPR88 allosteric agonists all have in vivo pharmacokinetic properties that preclude their progression to the clinic, including high lipophilicity and poor brain penetration. Here, we describe our attempts to improve GPR88 agonists' drug-like properties and our analysis of the trade-offs required to successfully target GPR88's allosteric pocket. We discovered two new GPR88 agonists: One that reduced morphine-induced locomotor activity in a murine proof-of-concept study, and the atropoisomeric BI-9508, which is a brain penetrant and has improved pharmacokinetic properties and dosing that recommend it for future in vivo studies in rodents. BI-9508 still suffers from high lipophilicity, and research on this series was halted. Because of its utility as a tool compound, we now offer researchers access to BI-9508 and a negative control free of charge via Boehringer Ingelheim's open innovation portal opnMe.com.

2024-07-01·British Journal of Pharmacology

Molecular insights into orphan G protein‐coupled receptors relevant to schizophrenia

Review

作者: Stewart, Gregory D ; Lu, Yao ; Hatzipantelis, Cassandra J ; Langmead, Christopher J

AbstractSchizophrenia remains a sizable socio‐economic burden that continues to be treated with therapeutics based on 70‐year old science. All currently approved therapeutics primarily target the dopamine D2 receptor to achieve their efficacy. Whilst dopaminergic dysregulation is a key feature in this disorder, the targeting of dopaminergic machinery has yielded limited efficacy and an appreciable side effect burden. Over the recent decades, numerous drugs that engage non‐dopaminergic G protein‐coupled receptors (GPCRs) have yielded a promise of efficacy without the deleterious side effect profile, yet none have successfully completed clinical studies and progressed to the market. More recently, there has been increased attention around non‐dopaminergic GPCR‐targeting drugs, which demonstrated efficacy in some schizophrenia symptom domains. This provides renewed hope that effective schizophrenia treatment may lie outside of the dopaminergic space. Despite the potential for muscarinic receptor‐ (and other well‐characterised GPCR families) targeting drugs to treat schizophrenia, they are often plagued with complications such as lack of receptor subtype selectivity and peripheral on‐target side effects. Orphan GPCR studies have opened a new avenue of exploration with many demonstrating schizophrenia‐relevant mechanisms and a favourable expression profile, thus offering potential for novel drug development. This review discusses centrally expressed orphan GPCRs: GPR3, GPR6, GPR12, GPR52, GPR85, GPR88 and GPR139 and their relationship to schizophrenia. We review their expression, signalling mechanisms and cellular function, in conjunction with small molecule development and structural insights. We seek to provide a snapshot of the growing evidence and development potential of new classes of schizophrenia therapeutics.LINKED ARTICLESThis article is part of a themed issue Therapeutic Targeting of G Protein‐Coupled Receptors: hot topics from the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists 2021 Virtual Annual Scientific Meeting. To view the other articles in this section visit http://onlinelibrary.wiley.com.libproxy1.nus.edu.sg/doi/10.1111/bph.v181.14/issuetoc

分析

对领域进行一次全面的分析。

或

查看完整样例数据

Eureka LS:

全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。